tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2021 Nov 10;1-15.
doi: 10.1080/21645515.2021.1990649. Online ahead of print.
A literature review of severity scores for adults with influenza or community-acquired pneumonia - implications for influenza vaccines and therapeutics
Katherine Adams[SUP] 1 [/SUP], Mark W Tenforde[SUP] 1 [/SUP], Shreya Chodisetty[SUP] 1 [/SUP], Benjamin Lee[SUP] 1 [/SUP], Eric J Chow[SUP] 1 [/SUP], Wesley H Self[SUP] 2 [/SUP], Manish M Patel[SUP] 1 [/SUP]
Affiliations
Abstract
Influenza vaccination and antiviral therapeutics may attenuate disease, decreasing severity of illness in vaccinated and treated persons. Standardized assessment tools, definitions of disease severity, and clinical endpoints would support characterizing the attenuating effects of influenza vaccines and antivirals. We review potential clinical parameters and endpoints that may be useful for ordinal scales evaluating attenuating effects of influenza vaccines and antivirals in hospital-based studies. In studies of influenza and community-acquired pneumonia, common physiologic parameters that predicted outcomes such as mortality, ICU admission, complications, and duration of stay included vital signs (hypotension, tachypnea, fever, hypoxia), laboratory results (blood urea nitrogen, platelets, serum sodium), and radiographic findings of infiltrates or effusions. Ordinal scales based on these parameters may be useful endpoints for evaluating attenuating effects of influenza vaccines and therapeutics. Factors such as clinical and policy relevance, reproducibility, and specificity of measurements should be considered when creating a standardized ordinal scale for assessment.
Keywords: Pneumonia; antiviral therapeutics; community-acquired pneumonia; infectious disease; influenza; influenza vaccine; prediction score; severity.
. 2021 Nov 10;1-15.
doi: 10.1080/21645515.2021.1990649. Online ahead of print.
A literature review of severity scores for adults with influenza or community-acquired pneumonia - implications for influenza vaccines and therapeutics
Katherine Adams[SUP] 1 [/SUP], Mark W Tenforde[SUP] 1 [/SUP], Shreya Chodisetty[SUP] 1 [/SUP], Benjamin Lee[SUP] 1 [/SUP], Eric J Chow[SUP] 1 [/SUP], Wesley H Self[SUP] 2 [/SUP], Manish M Patel[SUP] 1 [/SUP]
Affiliations
- PMID: 34757894
- DOI: 10.1080/21645515.2021.1990649
Abstract
Influenza vaccination and antiviral therapeutics may attenuate disease, decreasing severity of illness in vaccinated and treated persons. Standardized assessment tools, definitions of disease severity, and clinical endpoints would support characterizing the attenuating effects of influenza vaccines and antivirals. We review potential clinical parameters and endpoints that may be useful for ordinal scales evaluating attenuating effects of influenza vaccines and antivirals in hospital-based studies. In studies of influenza and community-acquired pneumonia, common physiologic parameters that predicted outcomes such as mortality, ICU admission, complications, and duration of stay included vital signs (hypotension, tachypnea, fever, hypoxia), laboratory results (blood urea nitrogen, platelets, serum sodium), and radiographic findings of infiltrates or effusions. Ordinal scales based on these parameters may be useful endpoints for evaluating attenuating effects of influenza vaccines and therapeutics. Factors such as clinical and policy relevance, reproducibility, and specificity of measurements should be considered when creating a standardized ordinal scale for assessment.
Keywords: Pneumonia; antiviral therapeutics; community-acquired pneumonia; infectious disease; influenza; influenza vaccine; prediction score; severity.